Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Abstract Session

Rheumatoid arthritis (RA)
General Topic: Clinical Science

12S166: Abstracts: RA – Treatments I: Novel RA Treatments & Mechanisms of Action (0835–0840)

Sunday, November 12, 2023
4:00 PM - 5:30 PM PT
Location: Room 6E/6D

On Demand In Person

    Presenting Author(s)

  • Matthew Baker, MD, MS

    Stanford University
    Menlo Park, CA, United States

    Disclosure(s): Beigene: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Mobility Bio: Consultant (Ongoing); Nēsos: Advisor or Review Panel Member (Terminated, October 1, 2018), Consultant (Terminated, October 1, 2018); Roivant: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Grant/Research Support (Ongoing); Zenas Biopharma: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing)

  • AC

    Andrew Cope, MD, PhD

    King's College London
    London, United Kingdom

    Disclosure information not submitted.

  • RR

    Russell Ross, PhD

    Sorrento Therapeutics
    Sandy Springs, GA, United States

    Disclosure information not submitted.

  • PT

    Peter Taylor, PhD, FRCP, MA

    University of Oxford
    Oxford, United Kingdom

    Disclosure information not submitted.

  • Xiaofeng Zeng, MD (he/him/his)

    Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology
    Beijing, Beijing, China

    Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

  • 4:00 PM - 4:10 PM PT
    Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial

    Presenting Author: Andrew Cope, MD, PhD – King's College London

  • 4:10 PM - 4:15 PM PT
    Q&A
  • 4:15 PM - 4:25 PM PT
    Vagotomy and Subsequent Risk of Rheumatoid Arthritis and Osteoarthritis: A Danish Register-Based Cohort Study

    Presenting Author: Matthew Baker, MD, MS – Stanford University

  • 4:25 PM - 4:30 PM PT
    Q&A
  • 4:30 PM - 4:40 PM PT
    A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis

    Presenting Author: Matthew Baker, MD, MS – Stanford University

  • 4:40 PM - 4:45 PM PT
    Q&A
  • 4:45 PM - 4:55 PM PT
    Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections

    Presenting Author: Russell Ross, PhD – Sorrento Therapeutics

  • 4:55 PM - 5:00 PM PT
    Q&A
  • 5:00 PM - 5:10 PM PT
    Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study

    Presenting Author: Peter Taylor, PhD, FRCP, MA – University of Oxford

  • 5:10 PM - 5:15 PM PT
    Q&A
  • 5:15 PM - 5:25 PM PT
    Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study

    Presenting Author: Xiaofeng Zeng, MD (he/him/his) – Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology

  • 5:25 PM - 5:30 PM PT
    Q&A